Literature DB >> 19933533

The successful management of severe protamine-induced pulmonary hypertension using inhaled prostacyclin.

Angela Jerath1, Coimbatore Srinivas, Annette Vegas, Stephanie Brister.   

Abstract

Acute pulmonary hypertension is a severe and life-threatening reaction that rarely occurs secondary to protamine administration. Management of systemic hypotension combined with severe pulmonary hypertension causing right ventricular failure is challenging. We describe a case of acute pulmonary hypertension induced by protamine during elective coronary artery bypass surgery refractory to multiple systemic inotropic and vasopressor therapies. After inhaled prostacyclin administration, our patient's pulmonary artery pressures decreased from 70/37 to 45/23 mm Hg within 10 min. The case highlights a role for inhaled nebulized prostacyclin as a selective pulmonary vasodilator with minimal systemic hypotensive effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933533     DOI: 10.1213/ANE.0b013e3181c6bbf0

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

1.  Efficacy of intraoperative transesophageal echocardiography in a case of protamine shock during transcatheter aortic valve implantation.

Authors:  Akihisa Kataoka; Yusuke Watanabe; Shutaro Seki; Shintaro Takamura; Hirofumi Hioki; Hiroyuki Kyono; Shigehito Sawamura; Ken Kozuma
Journal:  JA Clin Rep       Date:  2016-10-10

2.  Fatal right ventricular failure and pulmonary hypertension after protamine administration during cardiac transplantation.

Authors:  Bibek S Pannu; Devang K Sanghavi; Pramod K Guru; Dereddi Raja Reddy; Vivek N Iyer
Journal:  Indian J Crit Care Med       Date:  2016-03

3.  Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery.

Authors:  Zheng Guan; Xin Shen; Yong-Jian Zhang; Xiao-Gang Li; Yan-Feng Gao; Jing Tan; Hui Yuan; Jing-Jie Liu
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.